Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure

B. Daniel Lucas, Mark A. Williams, Syed M. Mohiuddin, Lance J. LaMadrid, Lisa J. Schroeder, Daniel E. Hilleman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Study Objective. To evaluate the effect of cimetidine, famotidine, ranitidine, and placebo on left ventricular systolic function, aerobic metabolic performance, and exercise capacity in patients with chronic, stable heart failure. Design. Double-blind, randomized, placebo-controlled, four- way crossover study. Setting. Outpatient, university-affiliated cardiology clinic. Patients. Twelve men with stable New York Heart Association class II or III heart failure secondary to ischemic heart disease or hypertension. Interventions. Patients received in random sequence cimetidine 400 mg twice/day, famotidine 40 mg/day, ranitidine 150 mg twice/day, and placebo. Each treatment was administered for 7 days, and the periods were separated by a 1-week washout. Measurements and Main Results. Before and after each treatment, patients underwent a bicycle stress echocardiogram with aerobic metabolic assessment. Left ventricular function was evaluated by calculating ejection phase indexes from Doppler echocardiographic measurements. All 12 patients successfully completed the study. No patient reported any adverse effect attributed to study drugs. None of the treatments was associated with significant changes in any measure of left ventricular systolic function, aerobic metabolic performance, or exercise capacity, nor were placebo- subtracted differences for the agents significantly different for any of the three measures. Conclusion. The three H2-receptor antagonists administered for 7 days at clinical dosages have no significant effect on left ventricular systolic function, aerobic metabolic performance, or exercise capacity in men with class II or III stable heart failure.

Original languageEnglish
Pages (from-to)824-830
Number of pages7
JournalPharmacotherapy
Volume18
Issue number4
StatePublished - 1998
Externally publishedYes

Fingerprint

Histamine H2 Receptors
Left Ventricular Function
Heart Failure
Exercise
Placebos
Famotidine
Ranitidine
Cimetidine
Cardiology
Cross-Over Studies
Myocardial Ischemia
Outpatients
Therapeutics
Hypertension
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure. / Lucas, B. Daniel; Williams, Mark A.; Mohiuddin, Syed M.; LaMadrid, Lance J.; Schroeder, Lisa J.; Hilleman, Daniel E.

In: Pharmacotherapy, Vol. 18, No. 4, 1998, p. 824-830.

Research output: Contribution to journalArticle

@article{c1cac459cd2f4f25b7e4a3712557c4b6,
title = "Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure",
abstract = "Study Objective. To evaluate the effect of cimetidine, famotidine, ranitidine, and placebo on left ventricular systolic function, aerobic metabolic performance, and exercise capacity in patients with chronic, stable heart failure. Design. Double-blind, randomized, placebo-controlled, four- way crossover study. Setting. Outpatient, university-affiliated cardiology clinic. Patients. Twelve men with stable New York Heart Association class II or III heart failure secondary to ischemic heart disease or hypertension. Interventions. Patients received in random sequence cimetidine 400 mg twice/day, famotidine 40 mg/day, ranitidine 150 mg twice/day, and placebo. Each treatment was administered for 7 days, and the periods were separated by a 1-week washout. Measurements and Main Results. Before and after each treatment, patients underwent a bicycle stress echocardiogram with aerobic metabolic assessment. Left ventricular function was evaluated by calculating ejection phase indexes from Doppler echocardiographic measurements. All 12 patients successfully completed the study. No patient reported any adverse effect attributed to study drugs. None of the treatments was associated with significant changes in any measure of left ventricular systolic function, aerobic metabolic performance, or exercise capacity, nor were placebo- subtracted differences for the agents significantly different for any of the three measures. Conclusion. The three H2-receptor antagonists administered for 7 days at clinical dosages have no significant effect on left ventricular systolic function, aerobic metabolic performance, or exercise capacity in men with class II or III stable heart failure.",
author = "Lucas, {B. Daniel} and Williams, {Mark A.} and Mohiuddin, {Syed M.} and LaMadrid, {Lance J.} and Schroeder, {Lisa J.} and Hilleman, {Daniel E.}",
year = "1998",
language = "English",
volume = "18",
pages = "824--830",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure

AU - Lucas, B. Daniel

AU - Williams, Mark A.

AU - Mohiuddin, Syed M.

AU - LaMadrid, Lance J.

AU - Schroeder, Lisa J.

AU - Hilleman, Daniel E.

PY - 1998

Y1 - 1998

N2 - Study Objective. To evaluate the effect of cimetidine, famotidine, ranitidine, and placebo on left ventricular systolic function, aerobic metabolic performance, and exercise capacity in patients with chronic, stable heart failure. Design. Double-blind, randomized, placebo-controlled, four- way crossover study. Setting. Outpatient, university-affiliated cardiology clinic. Patients. Twelve men with stable New York Heart Association class II or III heart failure secondary to ischemic heart disease or hypertension. Interventions. Patients received in random sequence cimetidine 400 mg twice/day, famotidine 40 mg/day, ranitidine 150 mg twice/day, and placebo. Each treatment was administered for 7 days, and the periods were separated by a 1-week washout. Measurements and Main Results. Before and after each treatment, patients underwent a bicycle stress echocardiogram with aerobic metabolic assessment. Left ventricular function was evaluated by calculating ejection phase indexes from Doppler echocardiographic measurements. All 12 patients successfully completed the study. No patient reported any adverse effect attributed to study drugs. None of the treatments was associated with significant changes in any measure of left ventricular systolic function, aerobic metabolic performance, or exercise capacity, nor were placebo- subtracted differences for the agents significantly different for any of the three measures. Conclusion. The three H2-receptor antagonists administered for 7 days at clinical dosages have no significant effect on left ventricular systolic function, aerobic metabolic performance, or exercise capacity in men with class II or III stable heart failure.

AB - Study Objective. To evaluate the effect of cimetidine, famotidine, ranitidine, and placebo on left ventricular systolic function, aerobic metabolic performance, and exercise capacity in patients with chronic, stable heart failure. Design. Double-blind, randomized, placebo-controlled, four- way crossover study. Setting. Outpatient, university-affiliated cardiology clinic. Patients. Twelve men with stable New York Heart Association class II or III heart failure secondary to ischemic heart disease or hypertension. Interventions. Patients received in random sequence cimetidine 400 mg twice/day, famotidine 40 mg/day, ranitidine 150 mg twice/day, and placebo. Each treatment was administered for 7 days, and the periods were separated by a 1-week washout. Measurements and Main Results. Before and after each treatment, patients underwent a bicycle stress echocardiogram with aerobic metabolic assessment. Left ventricular function was evaluated by calculating ejection phase indexes from Doppler echocardiographic measurements. All 12 patients successfully completed the study. No patient reported any adverse effect attributed to study drugs. None of the treatments was associated with significant changes in any measure of left ventricular systolic function, aerobic metabolic performance, or exercise capacity, nor were placebo- subtracted differences for the agents significantly different for any of the three measures. Conclusion. The three H2-receptor antagonists administered for 7 days at clinical dosages have no significant effect on left ventricular systolic function, aerobic metabolic performance, or exercise capacity in men with class II or III stable heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0032113804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032113804&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 824

EP - 830

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 4

ER -